
Our Therapeutic Pipeline
At conveyxo, we’re dedicated to pioneering new treatments that benefit patients.
We develop RNA-enhanced therapeutics exosomes to reverse the root cause of inflammatory conditions and degenerative diseases.
Our pipeline represents our commitment to transforming patient care, with programs in discovery, through pre-clinical development, to clinic in early 2027.
Conveyxo RNA-enhanced exosomes pipeline
Current treatments for degenerative and inflammatory diseases only manage symptoms, not their root cause, leaving a massive unmet need.
Conveyxo develops RNA-enhanced exosomes designed to reduce inflammation, restore cellular balance, and address degenerative diseases at their biological roots.
Our lead programs focus on osteoarthritis (EXOSTEO01) and dermatological conditions (DERMEXO01), with a path toward first-in-human studies.

Expanding Indications Through Strategic Partnerships
In collaboration with external research and industry partners, we extend our exosome platform into additional therapeutic areas. These joint programs broaden our impact and accelerate development across inflammation-driven diseases.

